HNSCC (Head & Neck Squamous Cell Carcinoma) is cancer that develops in mucous membranes of the mouth, throat, & nose and showcases severe symptoms like:
The Oral Cavity, Paranasal Sinuses, Nasal Cavity, Oropharynx, Larynx, Hypopharynx, & Nasopharynx are various locations where HNSCC can occur. In case of late detection or non-treatment, it can also spread across other parts like the lungs or lymph nodes, making the situation fatal. Hence, with the criticality of addressing such health conditions, several governments & prominent biopharma companies are actively participating in various research & development activities to bring innovations in therapeutics and cater to the unmet patient needs worldwide.
The Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market is projected to grow at around 9.5% CAGR during the forecast period, i.e., 2022-27. The growth of the market is driven primarily by the mounting prevalence of HNSCC, i.e., augmenting the demand for diagnosis & treatment and, in turn, instigating governments of different countries to increase their respective healthcare expenditures for drug developments to cater to the high unmet requirements of patients worldwide.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Regions Covered||North America: The US, Canada, Mexico|
|South America: Brazil, Rest of Latin America|
|Europe: Germany, The UK, France, Italy, Spain, Rest of Europe|
|Middle East & Africa: GCC, South Africa, Rest of Middle East and Africa|
|Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific|
|Key Companies Profiled||AbbVie Inc., AstraZeneca PLC, Amgen Inc., Bayer AG, Bristol Myers Squibb, DFG Oncology, Dr. Reddy’s Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, Jiangsu Hengrui, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Others|
|Unit Denominations||USD Million/Billion|
As several countries are laying out favorable policies for the research & development and clinical trials of novel drugs, the global market is observing the active participation of the leading players. The primary causes of HNSCC include smoking, alcohol consumption, HPV (Human Papillomavirus) infection for oropharyngeal cancer, & EBV (Epstein-Barr Virus) infection for nasopharyngeal cancer.
Governments worldwide are encouraging several research institutions to indulge immensely in developing effective chemotherapy & immunotherapy drugs for the treatment of HNSCC patients. Moreover, they are also spreading awareness among people about the ill effects of smoking & alcohol consumption and the availability of effective diagnosis & treatment for HNSCC.
Additionally, they are massively investing in the oncology sector, pharmaceutical giants, cancer associations, and other organizations for the research & development associated with HNSCC therapeutics, thereby generating lucrative opportunities for the various companies participating in the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market.
Moreover, as treatments like chemotherapy are being adopted extensively by patients across different corners of the world, the demand for drugs like Docetaxel, Cisplatin, & Bleomycin, among others, is rising swiftly and, in turn, instigating the leading biopharma companies to increase their production & distribution capacities in order to cater to the high unmet patient needs